# US 2021/0063400 A1 · Renal cancer detection method and test drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0063400 A1
- Document ID: US20210063400A1
- Status: Published application
- Kind: A1
- Application number: 16/962,352
- Filed: 2018-12-26
- Published: 2021-03-04
- Earliest claimed: 2018-01-16
- Assignees: Public University Corporation Yokohama City University; Tosoh Corporation
- Applicants: Public University Corporation Yokohama City University; Tosoh Corporatio
- Inventors: Noriaki ARAKAWA; Hisashi HIRANO; Noboru NAKAIGAWA; Masahiro YAO; Norihisa OHTAKE
- Web page: https://patentgrep.com/patent/US20210063400A1

## CPC

- G01N 33/57525: of the liver or pancreas
- G01N 33/5754: of the renal system, e.g. kidneys or ureters
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An object of the present invention is to provide a method for detecting renal cancer, and a reagent that can be used for the method. Provided is a method for detecting renal cancer, which includes measuring the amount of TFPI2 in a sample derived from a patient. An antibody that specifically recognizes NT-TFPI2 and intact TFPI2 is included in a detection reagent for renal cancer.

## Claims

### Claim 1

A method for detecting renal cancer, said method comprising measuring the amount of TFPI2 in a sample.

### Claim 2 (depends on 1)

The method according to claim 1, wherein renal cancer is detected when said measured amount of TFPI2 exceeds a predetermined standard value.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said amount of TFPI2 is the sum of the amount of TFPI2 processing polypeptide and the amount of intact TFPI2.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said amount of TFPI2 is measured by an antigen-antibody reaction using an antibody that binds to an antigenic determinant in the region from the 23rd residue aspartic acid to the 131st residue histidine or the 130th residue cysteine of the amino acid sequence of SEQ ID No:1.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said antibody is an antibody that recognizes Kunitz domain 1 of TFPI2.

### Claim 6 (depends on 1)

The method according to claim 1, wherein measurement is carried out using mass spectrometry.

### Claim 7

A reagent for detecting renal cancer, comprising an antibody that binds to an antigenic determinant in the region from the 23th residue aspartic acid to the 131st residue histidine or to the 130th residue cysteine in the amino acid sequence of SEQ ID NO:1.
